RNU1-2: RNU1-2 is a member of the RNA U1 family and is a non-polyadenylated uridine-rich small nuclear RNA (UsnRNA) [PMC4931115]. The impact of BRAT1 deletion on the 3' end processing of non-polyadenylated UsnRNAs, including RNU1-2, was investigated using quantitative reverse-transcription PCR (RT-qPCR) [PMC9418311]. The role of RNU1-2 in innate immune activation was further supported by the finding that alterations in RNU1-2 expression were associated with innate immune activation [PMC5815369]. RNU1-2, along with other genes from the RNA U1 family, regulates transcription, elongation, and pre-mRNA splicing events [PMC5062749]. Transcription read-through was observed at the RNU1-2 locus upon depletion of ARS2 and CBP80 [PMC3923317]. Up-regulation of RNU1-2 has been observed in KSHV+ PEL cell lines treated with a c-MET inhibitor [PMC5578886]. RNU43 is commonly used as a reference gene along with RNU1-2 in urological cancers [PMC8999557]. The stability of SNORD43 and its combination with RNU1-2 as reference genes has been demonstrated for studying c-miRNAs in urological malignancies [PMC6769746]. Functional roles have been identified for genes such as MALAT1, FENDRR, TUG1, and RNU1-2 in cell cycle regulation and splicing cycle events [PMC7290873]. In various studies, expression changes have been observed for genes such as SLC7A11 and KRTAP2-3 along with RNU11 upon different treatments or conditions [PMC8997840] [PMC7093963]. RNU1-2 has also been associated with maternal race effects [PMC8796169]. RNU1-2 is one of the genes induced upon PTS and is involved in transcript splicing [PMC7907328]. Additionally, RNU1-2 has been identified as a significantly differentially expressed gene in the analysis of STIR volume and STIR composite [PMC8741947].